Tagged with manufacturing,

France Skyepharma stands at a defining moment. With new shareholders, expanding high-potency and bioproduction capabilities and a sharpened focus on complex oral forms, the French CDMO is positioning itself for a new phase of growth at the intersection of innovation, sovereignty and international ambition. In this conversation, recently appointed CEO Sébastien…

MEA Some of the top recent stories from pharma and healthcare in the Middle East and Africa, including Saudi Arabia’s pharma pitch to US investors, a new fund to bring forward Saudi biotechs, Egypt’s collaboration with Turkey on pharma manufacturing, and China’s ‘health silk road’ in Africa.   Saudi Arabia pitches…

France Under the leadership of Nicolas Bardonnet, Promega France has expanded its role from a broad portfolio provider to a more collaborative partner supporting key human health applications. Bardonnet has integrated elements of a One Health approach, establishing France as a key European application & training centre, with plans for continued…

France With over 25 years of experience at the crossroads of science and business, Pascal Villemagne, CEO of SEQENS, shares his vision for steering the French CDMO into a new era of innovation, sustainability, and global partnership. From expanding into advanced therapies and accelerating pharmaceutical development to championing France’s industrial renewal,…

Switzerland Manufacturing – long sidelined as a relatively prosaic element of the global pharma supply chain – is back in the news. Investment in manufacturing facilities is skyrocketing as sponsors rush to meet soaring market demand, and the global industry is scrambling to align with the Trump administration’s threats and incentives…

France France is undergoing a quiet industrial renaissance in biomanufacturing, driven by a growing alignment between science, innovation, and policy. At the centre of this movement stands Laurent Lafferrère, CEO of France BioLead, who is leading efforts to structure the country’s ecosystem, foster collaboration, and attract sustainable investment. In this conversation,…

USA Global pharma is rushing to relocate manufacturing to the US. To reduce dependence on foreign manufacturing sources – most notably from its main economic adversary, China – the Trump administration is putting pressure on pharma to situate production on US soil. This pressure is predominantly taking the form of economic…

Denmark Drawn from Healthcare & Life Sciences Review Denmark 2025, this selection captures the major forces now reshaping one of Europe’s most dynamic life science hubs. From Denmark’s bid to double the sector’s economic weight by 2030, to its sweeping “Health Closer to You” reform, biotech surge, clinical-trials strategy, and evolving…

Mexico Adriana Eguia Alaniz is President of Tijuana EDC, leading efforts to diversify and strengthen the region’s economy. Under her leadership, Tijuana has strengthened its role as a major medical device export hub, with 55,000 workers, $3B in exports, and 40+ global companies. Her priorities include cross-border speed-to-market, supply chain resilience,…

LatAm Vaccination remains the most powerful public health intervention ever devised, preventing an estimated 4.4 million deaths each year, according to the WHO. Yet with misinformation spreading faster than science, and routine immunisation disrupted by pandemic aftershocks, even long-protected regions are witnessing a resurgence in preventable diseases. In Latin America, where…

USA Norman Stoffregen, SVP and Site Head at Enzene Inc., explains how the US arm of India’s Enzene Biosciences is introducing its cost-efficient, continuous manufacturing model to the US CDMO market. With a state-of-the-art facility in Hopewell, New Jersey, Enzene supports mid-sized biopharma clients with flexible, small-footprint biologics production. By combining…

Switzerland Marcel Imwinkelried, CEO of Siegfried, leads a CDMO specialising in small molecules with comprehensive global manufacturing capabilities. His “Evolve Plus” strategy focuses on operational excellence, selective biologics growth, and disciplined acquisitions to ensure sustainable expansion. Under his leadership, Siegfried prioritises innovation, sustainability, and talent development to deliver lasting value to…